ART-Plan™: AI-Powered Radiotherapy
An intelligent software for high-precision radiotherapy, ART-Plan™ optimizes every step of the treatment process flow: from preparation to follow-up.
Coming soon
- SmartPlan:
- MR-Dose:
- and more solutions for real adaptive radiotherapy


ART-Plan™: Are you ready to reinvent cancer care through AI?
Through ART-Plan™, we leverage state-of-the-art advancements in artificial intelligence, data science and medical image processing for better radiotherapy experience for your patients and medical teams alike.
Up to 95% of time saved in contouring
Full-body expert-like contours in 3 minutes
+100 OARs & LNs delineated automatically
+40 centres using ART-Plan™ in Europe
+50 000 patients treated with ART-Plan™
CE-marked and FDA-/TGA-Cleared
Discoverwhatwe do
AI-Powered Biomarker Discovery
Biomarkers can be make the vision of more effective and personalizes treatment a reality. As such, biomarkers can help improve safety and efficacy during drug development, select patients for clinical trials or monitor patient response and treatment efficacy.

ART-Omics™
ART-Omics™, the first AI-powered, plug-n-play, radiomics platform, is a unique combination of unsupervised biomarker discovery and clinical domain knowledge for advanced diagnosis, prognosis and disease monitoring.
Soon, ART-Omics™ will provide tailor-made AI-based, radiomic algorithms and become a strategic ally to pharmaceutical companies who wish to accelerate therapeutic development and reduce costs related to long and unsuccessful trials.
Who are we?
Innovative
At TheraPanacea, an award-winning medical technology company created in 2017, we are harnessing AI to develop cutting-edge software for more efficient and precise cancer care. We offer pioneering holistic approaches for cancer research and treatment based on a multi-scale integration of medicine, information theory, data curation and computational medicine.
Devoted
A vastly experienced team, we are devoted to unlock the unlimited power of AI-based software to drive innovation in healthcare. Endowed with an excellent IP portfolio, our vision is to exploit state-of-the-art research technology to accelerate health care’s transition towards predictive, evidence-driven, adaptive treatment planning and delivery.
Humane
Our mission is to improve the quality of life of each patient by enabling health care providers to design smarter treatment plans, work more effectively, and reduce toxic side effects. To bring these much needed advancements faster to the patient, we count on valuable collaborations with leading cancer centers and industrial partners all around the world.
From our Blog
Keep up with our latest news on our journey to reinvent cancer care and join us for our future events.
5 May 2022
ESTRO 2022
22 December 2021
Biogen & TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
December 14, 2021 - 13:00 CET The aim…
11 October 2021